Aa
A
A
Close
Avatar universal
U.S. court invalidates patent on Bristol hepatitis B drug
A U.S. federal court has invalidated the U.S. patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.

"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.  

Bristol-Myers had filed suit against Israeli drugmaker Teva in 2010 to block introduction of its generic form of Baraclude. Hortas said the drug's chemical patent lapses in February 2015, but declined to comment on whether U.S. regulators might allow Teva's generic onto the market before then.

Teva officials could not immediately be reached for comment.

ISI Group analyst Mark Schoenebaum said the U.S. Food and Drug Administration would have to approve Teva's marketing application before its generic could be introduced, and that it was unclear when the FDA might act.

Schoenebaum said Baraclude is expected to have U.S. sales this year of about $260 million. Even if the Teva generic arrives this year and hurts Baraclude's U.S. sales, he said Bristol-Myers will probably not need to lower its current full-year profit forecast.

Shares of Bristol-Myers were down 0.6 percent at $36.69 on the New York Stock Exchange on Tuesday morning. Teva shares were down 0.4 percent in Tel Aviv.

http://newsandinsight.thomsonreuters.com/Legal/News/2013/02_-_February/U_S__court_invalidates_patent_on_Bristol_hepatitis_B_drug/
Cancel
6 Answers
Page 1 of 1
Avatar universal
This is a good wake up call for Bristol Myers to by or partner with Replicor.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
so will baraclude be forbidden as a consequences of this invalidation ?
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
so ,

the price will reduce sooon .. every hbver can get the medicine all over the world ..
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
Baraclude generates $250+ million USD per year for BMS.  The drug is patented for 10 years so thats rougly $2.5 billion USD for BMS.

It would be in thier best interest to develop better drugs for the Hepatitis B market and have them available after the patent expires. Considering thier is a lot of potential to treat people, drug manufacturers should jump on the Hepatitis B market.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
$250 million of USD is only USA market. Take into account rest of the world and there will be billions in just a month.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
is that means the entecavir will become chaper and cheaper by this year 2013?
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Your Answer
Avatar universal
Answer
Do you know how to answer? Tap here to leave your answer...
Answer
Answer
Post Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources